| Product No | EMEA/H/C/004806 |
|---|---|
| Brand Name | Takhzyro |
| Nonproprietary Name | lanadelumab |
| API | lanadelumab |
| ATC Code | B06AC05 |
| Indications | Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. |
| Orphan Drug | yes |
| Generics | no |
| Marketing Authorization Holder | Takeda Pharmaceuticals International AG Ireland Branch |
| Status | Authorised(授权) |
| Authorization Date | 2018-11-22 |
| Version | 10 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information